Fierce Pharma

NOVEMBER 4, 2024

The deal is expected to extend Nektar's cash runway into 2026 and help the company hone its development of novel immunology drugs.

Manufacturing 187

Manufacturing Sales 187

Fierce Pharma

OCTOBER 30, 2024

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.

Prospecting 291

Prospecting Medicine FDA 291

Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

286

286

MedCity News

AUGUST 15, 2024

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

Competition 325

Competition Biopharma Pharma 325

MedCity News

OCTOBER 3, 2024

The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE.

Biopharma 316

Biopharma Pharma 316

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

Sales 263

Sales 263

MedCity News

MARCH 28, 2025

Medicaid and SNAP cuts could lead to 1 million jobs lost in just 2026, according to a new report from the Commonwealth Fund and the George Washington University Milken Institute School of Public Health. The post Report: How Medicaid/SNAP Cuts Could Affect the Economy appeared first on MedCity News.

Leads 276

Leads 276

MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 290

Biopharma Pharma 290

PharmaVoice

OCTOBER 23, 2024

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

246

246

pharmaphorum

OCTOBER 24, 2024

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.

Pharma 105

Pharma 105

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 304

Biopharma Government 304

Fierce Pharma

MARCH 18, 2024

As bluebird bio works to make the most of three gene therapy launches, cash-flow concerns have been looming over the drugmaker. | The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches.

284

284

European Pharmaceutical Review

SEPTEMBER 12, 2023

Over 50 percent of respondents answered that machine learning for optimisation of manufacturing processes will be the technology that will be used routinely in the pharmaceutical industry by 2026. The post AI to revolutionise drug development by 2026 appeared first on European Pharmaceutical Review.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Pharmaceutical FDA 105

Fierce Pharma

SEPTEMBER 3, 2024

28, 2026. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

Manufacturing 263

Manufacturing Sales Medical 263

Pharmaceutical Technology

JUNE 19, 2025

BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory in space in 2026. Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Image credit: Rini. com/ Shutterstock.

Manufacturing 52

Manufacturing Media Pharmaceutical Government 52

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 246

Healthcare Healthcare 246

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 287

FDA Pharma 287

Fierce Pharma

JANUARY 4, 2024

The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

Manufacturing 287

Manufacturing 287

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Sales 98

Sales Biopharma Manufacturing Pharma 98

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. percent between 2021 and 2026 (the forecast period). Billion by 2026, achieving a 5.6 billion by 2026, as contract manufacturing organisations increasingly adopt newer and efficient ways to package products, increasing demand for new machinery. billion by the year 2026. Within the $130.2

Manufacturing 98

Manufacturing Marketing Pharma Pharmaceutical 98

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 272

Sales 272

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

Sales 276

Sales 276

Pharmatutor

MAY 29, 2025

THE PATENT & TRADE MARK AGENT EXAMINATION 2026 Rajesh Vagh Thu, 05/29/2025 - 13:37 The Trade Mark & Patent Agent Examination 2026 Shall be conducted on January 10th and 11th respectively at locations Ahmedabad, Bangalore, Bhopal, Chandigarh, Chennai, Delhi, Guwahati, Hyderabad, Kolkata, Lucknow, Mumbai, Nagpur and Thiruvananthapuram.

Training 40

Training Engineering Government Consulting 40

PharmaVoice

MARCH 11, 2025

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

179

179

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

Medical 233

Medical 233

MedCity News

FEBRUARY 12, 2025

Centivo and Premise Health are launching a new primary care-focused health plan that will become available to employers in the 2026 benefits cycle. The post Centivo, Premise Health Strike Partnership to Create Primary Care-Focused Health Plan appeared first on MedCity News.

179

179

Fierce Pharma

NOVEMBER 12, 2024

The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way. . | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5

Manufacturing 187

Manufacturing 187

Fierce Pharma

JUNE 10, 2024

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.

Prescription 187

Prescription Marketing 187

PharmaVoice

AUGUST 16, 2024

The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.

147

147

World of DTC Marketing

MAY 9, 2022

Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. billion by 2026 , is still a new frontier of the digital world, an all but lawless Wild West where a few major industry players have seized territory for their gain. Online ad fraud is costing pharma millions.

Pharma 264

Pharma Media Marketing Sales 264

Pharmaceutical Technology

MAY 21, 2025

Despite the boost to contributions, WHO has downsized its 2026-27 budget by over $1bn due to financial constraints.

52

52

PharmaVoice

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

Marketing 130

Marketing 130

Pharmaceutical Technology

NOVEMBER 19, 2024

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52

52

World of DTC Marketing

JULY 28, 2022

Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. Consequently, drug companies can set prices as high as the market will bear, meaning the government has no choice but to cover many medications at unfair prices.

Pharma 306

Pharma Prescription Pharmaceutical Manufacturing 306

Pharmacy Times

MAY 27, 2025

Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced their recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 1 variant that has become dominant in the US.

FDA 38

FDA 38

pharmaphorum

MAY 28, 2025

Savara shares are pummelled after the FDA says it cannot accept a filing for lead drug Molbreevi, but it is still hopeful of an approval in 2026.

Leads 45

Leads Manufacturing FDA 45

European Pharmaceutical Review

JUNE 6, 2025

Dr Pakola shared that the trial is anticipated to support a Biologics License Application (BLA) submission for the gene therapy under accelerated approval in mid-2026. Top-line data is expected in H1 of 2026. The post Duchenne gene therapy interim trial outcomes “striking” appeared first on European Pharmaceutical Review.

Safety 52

Safety Leads Medical Pharmaceutical 52